Compare KPTI & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | SAMG |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 112.1M |
| IPO Year | 2013 | 2013 |
| Metric | KPTI | SAMG |
|---|---|---|
| Price | $6.75 | $15.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | ★ 174.4K | 37.8K |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 5.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $142,530,000.00 | $125,322,000.00 |
| Revenue This Year | $3.82 | $3.44 |
| Revenue Next Year | $3.18 | $9.39 |
| P/E Ratio | ★ N/A | $21.14 |
| Revenue Growth | N/A | ★ 4.23 |
| 52 Week Low | $3.51 | $13.23 |
| 52 Week High | $12.45 | $19.20 |
| Indicator | KPTI | SAMG |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 62.98 |
| Support Level | $5.70 | $14.48 |
| Resistance Level | $7.48 | $15.52 |
| Average True Range (ATR) | 0.45 | 0.46 |
| MACD | 0.16 | 0.17 |
| Stochastic Oscillator | 69.78 | 86.07 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.